Apex Labs Ltd., a pharmaceutical company at the forefront of mental health treatment using psilocybin, is excited to announce the submission of a provisional patent application to the United States Patent and Trademark Office

Mind Medicine Inc., a company specializing in the development of treatments for brain health disorders, has received a breakthrough designation from the FDA for its MM120 program aimed at treating generalized anxiety disorder

Ludwig Enterprises, Inc, a US-based biotechnology company, is excited to announce the successful filing of its provisional patent titled "mRNAs Differentially Expressed in Colorectal Cancer,

Mainz Biomed N.V, a leader in molecular genetics diagnostic solutions for early cancer detection, has announced a strategic collaboration with Trusted Health Advisors, a prominent player in supporting the launch and management

YolTech Therapeutics, a leading biotechnology company specializing in in vivo gene editing therapies for rare genetic diseases, has achieved a significant milestone with the approval of the YOLT-201 investigational new drug application by the Center for Drug Evaluation

Vivoryon Therapeutics N.V. recently disclosed the top-line findings from its Phase 2b European VIVIAD trial of varoglutamstat , an oral glutaminyl cyclase inhibitor being explored for early Alzheimer’s disease

Coave Therapeutics, a genetic medicine company focused on developing innovative therapies, is pleased to announce its receipt of a grant from the ALS Association, part of a $2.9 million allocation to six organizations. These grants support the advancement

NeuroBo Pharmaceuticals, Inc. has obtained its first site Institutional Review Board approval from Dr. Alexander Prezioso, Investigator at Clinical Pharmacology of Miami in Hialeah, FL, to initiate the Phase 1 clinical trial

Form Bio and Ginkgo Bioworks have unveiled an innovative collaboration to revolutionize AAV gene therapy design and development. This partnership combines Ginkgo's expertise in cell programming and biosecurity

Incyte has disclosed that the U.S. Food and Drug Administration has accepted the Biologics License Application for axatilimab, an anti-CSF-1R antibody, for Priority Review. This application targets the treatment of chronic graft-versus-host disease